An Exploratory/Proof of Concept Investigation of the Safety and Pharmacodynamics of LY2127399 in HLA-Presensitized Patients With End-Stage Renal Disease Awaiting Transplantation

Trial Profile

An Exploratory/Proof of Concept Investigation of the Safety and Pharmacodynamics of LY2127399 in HLA-Presensitized Patients With End-Stage Renal Disease Awaiting Transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2016

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Renal failure; Renal transplant rejection
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Jan 2016 Primary endpoint of change from baseline through 76 weeks in Panel Reactive Antibodies (PRA) has been met, according to resultd published in the American Journal of Transplantation.
    • 18 Jan 2016 Results published in the American Journal of Transplantation
    • 19 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top